en · de · es · fr · pt
cjc-1295-notes.peptides7501.com › Faq › Background And Molecular Design — Field Notes

Background And Molecular Design — Field Notes

By Editorial Desk · published 2026-05-11 · last reviewed 2026-06-13 · Faq

Maleimide chemistry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight, DAC formAbout 3647 DaVaries with salt form
Molecular weight, non-DAC formAbout 3358 DaMOD GRF(1-29)
Solubility classWater solubleAlso dissolves in polar solvents
Reported half-life, DAC formAbout five to eight daysValues from human studies
Common synonymsCJC-1295; MOD GRF(1-29)Name depends on variant

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Related pages on this site

Handling, Stability and Analysis

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Albumin Binding and Duration of Action

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

Supporting material

Salvinorin B ethoxymethyl ether, also known as 2-O-ethoxymethylsalvinorin B (2-EMSB) or as symmetry, is a semi-synthetic analogue of the natural product salvinorin A, the psychoactive chemical in Salvia Divinorum, with a longer duration of action of around 3 hours (compared to less than 30 minutes for salvinorin A), and increased affinity and intrinsic activity at the κ-opioid receptor. Like the related compound herkinorin, 2-EMSB is made from salvinorin B, which is most conveniently made from salvinorin A by deacetylation, as while both salvinorin A and salvinorin B are found in the plant Salvia divinorum, salvinorin A is present in larger quantities. 2-EMSB has an affinity (Ki) of 0.32 nM at the κ-opioid receptor, and around 3,000 times selectivity over the μ- and δ-opioid receptors, making it one of the most potent and selective κ-opioid receptor agonists yet discovered. In animal studies it fully substituted for salvinorin A and the synthetic κ-opioid receptor agonist U-69593, and was active at doses as low as 0.005 mg/kg. Human bioassays found the compound to be active at 50 μg smoked. It has been sold online as an analytical standard.

=== Structural proteomics === A third area of Borchers' research is structural proteomics, which combines protein chemistry methods—such as cross-linking, hydrogen–deuterium exchange and photoaffinity labelling—with mass spectrometry and molecular modelling to study protein structure and interactions. This work includes the study of protein folding and misfolding associated with diseases such as Parkinson's disease and cystic fibrosis. In 2011, Borchers co-founded the Symposium on Structural Proteomics with Evgeniy Petrotchenko, and the two have co-organized the international meeting annually since.

In the Buddhist Abhidharma traditions like the Theravāda, more systematized explanations of the twelve nidanas developed. As an expository device, the commentarial traditions of the Theravāda, sarvāstivāda-vaibhasika and sautrantika schools defended an interpretation which saw the 12 factors as a sequence that spanned three lives. This is sometimes referred to as the "prolonged" explanation of dependent origination. The three life interpretation can first be seen in the Paṭisambhidāmagga (I.275, circa 2nd or 3rd c. BCE). It is also defended by the Theravāda scholar Buddhaghosa (c. fifth century CE) in his influential Visuddhimagga (Vism.578–8I) and it became standard in Theravada. The three-lives model, with its "embryological" interpretation which links dependent origination with rebirth was also promoted by the Sarvāstivāda school as evidenced by the Abhidharmakosa (AKB.III.21–4) of Vasubandhu (fl. 4th to 5th century CE) and the Jñanaprasthana. Wayman notes that this model is also present in Asanga's Abhidharmasamuccaya and is commented on by Nagarjuna. The three lives interpretation can be broken down as follows:

Cases of stigmatism fall into two categories: self-inflicted wounds, which may be either cases of fraud or of unconscious self-infliction, and those that are caused by emotional states ... Self-induced (through autosuggestion) itching and subsequent scratching of which the individual is unaware is likely to occur in suggestible persons if the stimulus is a mental or actual picture of the Crucifixion used during meditation and if the main motive is to receive the stigmata. The motive behind that may be unconscious conflict and a desire to escape from an intolerable situation into invalidism where one's needs are taken care of. It then becomes a case of hysterical conversion reaction. Many cases of stigmatism can be explained as fraud or unconsciously self-inflicted wounds. In his Stigmata: A Medieval Phenomenon in a Modern Age, Ted Harrison suggests that there is no single mechanism whereby the marks of stigmata were produced. Harrison found no evidence from a study of contemporary cases that the marks were supernatural in origin. He concluded, however, that marks of natural origin need not be hoaxes. Some stigmatics marked themselves in attempt to suffer with Christ as a form of piety. Others marked themselves accidentally and their marks were noted as stigmata by witnesses. Often marks of human origin produced profound and genuine religious responses. Harrison also noted that after Saint Francis of Assisi, the stigmata was "seen as a predominantly female experience" with the female-to-male ratio of stigmatics being 7 to 1.

===== Chain of two decays ===== Now consider the case of a chain of two decays: one nuclide A decaying into another B by one process, then B decaying into another C by a second process, i.e. A → B → C. The previous equation cannot be applied to the decay chain, but can be generalized as follows. Since A decays into B, then B decays into C, the activity of A adds to the total number of B nuclides in the present sample, before those B nuclides decay and reduce the number of nuclides leading to the later sample. In other words, the number of second generation nuclei B increases as a result of the first generation nuclei decay of A, and decreases as a result of its own decay into the third generation nuclei C. The sum of these two terms gives the law for a decay chain for two nuclides:

Sources: en.wikipedia.org

Supporting material

Cl2 + H2O → HOCl + HCl CH2=CH2 + HOCl → HO–CH2CH2–Cl CH2=CH2 + Cl2 → Cl–CH2CH2–Cl To suppress the conversion of ethylene into the ethylene dichloride (the last reaction), the concentration of ethylene is maintained at about 4–6%, and the solution is heated by steam to the boiling point. Next, aqueous solution of ethylene chlorohydrin enters the second column, where it reacts with a 30% solution of calcium hydroxide at 100 °C (212 °F):

Hans Keller (11 March 1919 – 6 November 1985) was a Viennese Jewish British musician and prolific writer, who made significant contributions to musicology and music criticism; best known for his appearance on TV show The Look of the Week in which he interviewed Syd Barrett and Roger Waters. Keller was generally puzzled by, or even contemptuous of, the group and its music, opening with the comment "why has it all got to be so terribly loud?" Judith Kerr, OBE (surname pronounced /ˈkɑːr/ KAR German pronunciation: [kɛʁ]; 14 June 1923 – 22 May 2019) was a German-born British writer and illustrator whose books sold more than 10 million copies around the world. She created both enduring picture books such as the Mog series and The Tiger Who Came to Tea and novels for older children such as the semi-autobiographical When Hitler Stole Pink Rabbit, which gave a child's-eye view of escaping Hitler's persecution in the Second World War. Born in the Weimar Republic, she came to Britain with her family in 1935 to escape persecution during the rise of the Nazis. Gerald Kersh, novelist Beeban Kidron, Baroness Kidron, (b.

LigoLab Information System is an American software company that provides software and laboratory operating systems for clinical laboratories. LigoLab develops and distributes the software tool TestDirectly, which is used for COVID-19 testing. It is based in Glendale, California.

== History == Octreotide acetate was approved for use in the United States in 1988. In January 2020, approval of octreotide acetate in the United States was granted to Sun Pharmaceutical under the brand name Bynfezia Pen for the treatment of:

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

How do the DAC and non-DAC forms differ?

The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.

What receptor does it act on?

It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network